174 research outputs found
Characteristics and quality of life of patients presenting to cancer support centres: Patient rated outcomes and use of complementary therapies
Background: In order to effectively target and provide individualised patient support strategies it is crucial to have a comprehensive picture of those presenting for services. The purpose of this study was to determine the characteristics and patient rated outcomes of individuals presenting to SolarisCare cancer support centres and their choices regarding complementary and integrated therapies (CIT).Methods: A cohort with a current or previous cancer diagnosis aged 18 - 87 years presenting to a SolarisCare centre during a 5-day period completed a questionnaire. Four SolarisCare centres participated in the trial including regional and metropolitan locations. Outcomes included medical and demographic characteristics, CIT variables and patient rated outcomes (PROs) including quality of life (QoL).Results: Of the 95 participants (70.3%) who completed the survey, the mean age was 60.5 years with 62% currently receiving treatment. Eighty percent of the sample had at least one other comorbid condition, with the most popular CIT being relaxation massage. Of the PROs, QoL was significantly lower than norms for the Australian population and other mixed cancer populations. No notable differences were seen between genders, however significantly poorer outcomes were found for the younger age group. Fifty percent of the population did not meet physical activity recommendations, and musculoskeletal symptoms explained between 25-27% of variance in QoL.Conclusions: A greater understanding of the health profiles of patients presenting to supportive care centres and their use of CIT, provides Western Australian health professionals with key information to ensure the safety of supportive care practices, as well as fosters optimal patient outcomes and enhances the integration of supportive care strategies within mainstream medical care
Positive patient experiences in an Australian integrative oncology centre
Background: The purpose of this study was to explore the experiences of cancer patients\u27 utilising complementary and integrative therapies (CIT) within integrative oncology centres across Western Australia.Methods: Across four locations 135 patients accessed CIT services whilst undergoing outpatient medical treatment for cancer. Of the 135 patients, 66 (61 Β± 12 y; female n = 45; male n = 21) agreed to complete a personal accounts questionnaire consisting of open-ended questions designed to explore patients\u27 perceptions of CIT. All results were transcribed into nVivo (v9) and using thematic analysis, key themes were identified.Results: Of the 66 participants, 100% indicated they would recommend complementary therapies to other patients and 92% stated CIT would play a significant role in their future lifestyle . A mean score of 8 Β± 1 indicated an improvement in participants\u27 perception of wellbeing following a CIT session. Three central themes were identified: empowerment, support and relaxation. Fourteen sub-themes were identified, with all themes clustered into a framework of multifaceted views held by cancer patients in relation to wellbeing, role of significant others and control.Conclusions: Exploration of patients\u27 experiences reveals uniformly positive results. One of the key merits of the environment created within the centres is patients are able to work through their cancer journey with an increased sense of empowerment, without placing them in opposition to conventional medical treatment. In order to effectively target integrative support services it is crucial to explore the experiences of patients in their own words and use those forms of expression to drive service delivery
ΠΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΠΎΠΏΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠΉ ΡΡΠ°Π΅ΠΊΡΠΎΡΠΈΠΈ Π»Π΅ΡΠ°ΡΠ΅Π»ΡΠ½ΡΡ ΠΎΠ±ΡΠ΅ΠΊΡΠΎΠ²
Π Π°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΌΠ΅ΡΠΎΠ΄Ρ ΡΡΠ°Π²Π½ΠΈΠ²Π°Π½ΠΈΡ ΡΠ³Π»ΠΎΠ²ΡΡ
ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΏΠΎ ΡΠΏΠΎΡΠΎΠ±Ρ Π½Π°ΠΈΠΌΠ΅Π½ΡΡΠΈΡ
ΠΊΠ²Π°Π΄ΡΠ°ΡΠΎΠ²: ΠΌΠ΅ΡΠΎΠ΄ ΡΡΠ°Π²Π½ΠΈΠ²Π°Π½ΠΈΡ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΎΡΠ΄Π΅Π»ΡΠ½ΠΎ Π² ΠΊΠ°ΠΆΠ΄ΠΎΠΌ Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠΈ, ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°ΡΡΠΈΠΉ Π½ΡΠ»Π΅Π²ΠΎΠ΅ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΎΠΆΠΈΠ΄Π°Π½ΠΈΠ΅ ΡΠ»ΡΡΠ°ΠΉΠ½ΡΡ
ΠΎΡΠΈΠ±ΠΎΠΊ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠΉ, ΠΈ ΠΌΠ΅ΡΠΎΠ΄ ΡΡΠ°Π²Π½ΠΈΠ²Π°Π½ΠΈΡ ΠΈΠ·Π±ΡΡΠΎΡΠ½ΡΡ
ΠΎΠΏΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠΉ Ρ ΠΏΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΈΡ
ΠΏΠΎΡΡΠΎΡΠ½Π½ΡΡ
ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΈΠ±ΠΎΠΊ Π² ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΈ Π·Π°ΡΠΎΡΠ΅Π½Π½ΠΎΡΡΠΈ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΊΠ°ΠΊ ΡΠ»ΡΡΠ°ΠΉΠ½ΡΠΌΠΈ, ΡΠ°ΠΊ ΠΈ Π½Π΅ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΌΠΈ ΠΏΠΎ Π²Π΅Π»ΠΈΡΠΈΠ½Π΅ ΠΈ Π·Π½Π°ΠΊΡ ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΠΎΠ³ΡΠ΅ΡΠ½ΠΎΡΡΡΠΌΠΈ.Π ΠΎΠ·Π³Π»ΡΠ½ΡΡΠΎ ΠΌΠ΅ΡΠΎΠ΄ΠΈ Π·ΡΡΠ²Π½ΡΠ²Π°Π½Π½Ρ ΠΊΡΡΠΎΠ²ΠΈΡ
Π²ΠΈΠΌΡΡΡΠ²Π°Π½Ρ Π·Π° ΡΠΏΠΎΡΠΎΠ±ΠΎΠΌ Π½Π°ΠΉΠΌΠ΅Π½ΡΠΈΡ
ΠΊΠ²Π°Π΄ΡΠ°ΡΡΠ²: ΠΌΠ΅ΡΠΎΠ΄ Π·ΡΡΠ²Π½ΡΠ²Π°Π½Π½Ρ Π²ΠΈΠΌΡΡΡΠ²Π°Π½Ρ ΠΎΠΊΡΠ΅ΠΌΠΎ Π² ΠΊΠΎΠΆΠ½ΠΎΠΌΡ ΡΠ°ΡΠΎΠ²ΠΎΠΌΡ ΡΠΎΠ·ΡΡΠ·Ρ, ΡΠΎ ΠΏΠ΅ΡΠ΅Π΄Π±Π°ΡΠ°Ρ Π½ΡΠ»ΡΠΎΠ²Π΅ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ½Π΅ ΠΎΡΡΠΊΡΠ²Π°Π½Π½Ρ Π²ΠΈΠΏΠ°Π΄ΠΊΠΎΠ²ΠΈΡ
ΠΏΠΎΡ
ΠΈΠ±ΠΎΠΊ Π²ΠΈΠΌΡΡΡΠ²Π°Π½Ρ, Ρ ΠΌΠ΅ΡΠΎΠ΄ Π·ΡΡΠ²Π½ΡΠ²Π°Π½Π½Ρ Π½Π°Π΄Π»ΠΈΡΠΊΠΎΠ²ΠΈΡ
ΠΎΠΏΡΠΈΡΠ½ΠΈΡ
Π²ΠΈΠΌΡΡΡΠ²Π°Π½Ρ ΡΠ· Π·Π°Π³Π»ΡΡΠ΅Π½Π½ΡΠΌ ΡΡ
ΠΏΠΎΡΡΡΠΉΠ½ΠΈΡ
ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ½ΠΈΡ
ΠΏΠΎΡ
ΠΈΠ±ΠΎΠΊ Ρ ΠΏΡΠΈΠΏΡΡΠ΅Π½Π½Ρ Π·Π°ΡΠΌΡΡΠ΅Π½ΠΎΡΡΡ Π²ΠΈΠΌΡΡΡΠ²Π°Π½Ρ ΡΠΊ Π²ΠΈΠΏΠ°Π΄ΠΊΠΎΠ²ΠΈΠΌΠΈ, ΡΠ°ΠΊ Ρ Π½Π΅Π²ΡΠ΄ΠΎΠΌΠΈΠΌΠΈ Π·Π° Π²Π΅Π»ΠΈΡΠΈΠ½ΠΎΡ ΡΠ° Π·Π½Π°ΠΊΠΎΠΌ ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ½ΠΈΠΌΠΈ ΠΏΠΎΡ
ΠΈΠ±ΠΊΠ°ΠΌΠΈ.The methods of equalizing angular measurements according to the method of least squares are examined: the method of equalizing measurements separately in each temporary section, that assumes the zero mathematical expectation of the random errors of measurements, and the method of equalizing excessive optical measurements with suppression of their constant systematic errors under the assumption of the obstruction of measurements by systematic errors both random and unknowns by value and sign
Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus
Aims: Racemic ibuprofen is widely used for the treatment of preterm neonates with patent ductus arteriosus. Currently used bodyweight-based dosing guidelines are based on total ibuprofen, while only the S-enantiomer of ibuprofen is pharmacologically active. We aimed to optimize ibuprofen dosing for preterm neonates of different ages based on an enantiomer-specific population pharmacokinetic model. Methods: We prospectively collected 210 plasma samples of 67 preterm neonates treated with ibuprofen for patent ductus arteriosus (median gestational age [GA] 26 [range 24β30] weeks, median body weight 0.83 [0.45β1.59] kg, median postnatal age [PNA] 3 [1β12] days), and developed a population pharmacokinetic model for S- and R-ibuprofen. Results: We found that S-ibuprofen clearance (CLS, 3.98 mL/h [relative standard error {RSE} 8%]) increases with PNA and GA, with exponents of 2.25 (RSE 6%) and 5.81 (RSE 15%), respectively. Additionally, a 3.11-fold higher CLS was estimated for preterm neonates born small for GA (RSE 34%). Clearance of R-ibuprofen was found to be high compared to CLS (18 mL/h [RSE 24%]), resulting in a low contribution of R-ibuprofen to total ibuprofen exposure. Current body weight was identified as covariate on both volume of distribution of S-ibuprofen and R-ibuprofen. Conclusion: S-ibuprofen clearance shows important maturation, especially with PNA, resulting in an up to 3-fold increase in CLS during a 3-day treatment regimen. This rapid increase in clearance needs to be incorporated in dosing guidelines by adjusting the dose for every day after birth to achieve equal ibuprofen exposure
Ineffective Healthcare Technology Management in Beninβs Public Health Sector: The Perceptions of Key Actors and Their Ability to Address the Main Problems
Background: Low-income countries face many contextual challenges to manage healthcare technologies effectively,
as the majority are imported and resources are constrained to a greater extent. Previous healthcare technology
management (HTM) policies in Benin have failed to produce better quality of care for the population and costeffectiveness for the government. This study aims to identify and assess the main problems facing HTM in Beninβs
public health sector, as well as the ability of key actors within the sector to address these problems.
Methods: We conducted 2 surveys in 117 selected health facilities. The first survey was based on 377 questionnaires
and 259 interviews, and the second involved observation and group interviews at health facilities. The Temple-Bird
Healthcare Technology Package System (TBHTPS), tailored to the context of Beninβs health system, was used as a
conceptual framework.
Results: The findings of the first survey show that 85% of key actors in Beninβs HTM sector characterized the
system as failing in components of the TBHTPS framework. Biomedical, clinical, healthcare technology engineers
and technicians perceived problems most severely, followed by users of equipment, managers and hospital
directors, international organization officers, local and foreign suppliers, and finally policy-makers, planners and
administrators at the Ministry of Health (MoH). The 5 most important challenges to be addressed are policy,
strategic management and planning, and technology needs assessment and selection β categorized as major
enabling inputs (MEI) in HTM by the TBHTPS framework β and installation and commissioning, training and skill
development and procurement, which are import and use activities (IUA). The ability of each key actor to address
these problems (the degree of political or administrative power they possess) was inversely proportional to their
perception of the severity of the problems. Observational data gathered during site visits described a different set
of challenges including maintenance and repair, distribution, installation and commissioning, use and training and
personnel skill development.
Conclusion: The lack of experiential and technical knowledge in policy development processes could underpin
many of the continuing problems in Beninβs HTM system. Before solutions can be devised to these problems, it is
necessary to investigate their root causes, and which problems are most amenable to policy development
Facilitators and barriers for the implementation of exercise are medicine in routine clinical care in Dutch university medical centres:a mixed methodology study on clinicians' perceptions
Objectives Despite the many proven advantages of a physically active lifestyle in patient populations, prescription of exercise is currently not widely implemented in routine clinical practice. The aims of this study were twofold: (1) to assess perceptions of clinicians on the current practice of exercise is medicine (E=M) prescription in two Dutch university medical centres and (2) to determine their perceived barriers and facilitators for the implementation of E=M in routine clinical care in Dutch university medical centres. Design A mixed methodologies study, using both online questionnaires and semi-structured interviews. Setting Dutch university medical centres. Participants Clinicians working within the departments of medical oncology, orthopaedics and rehabilitation medicine of two university medical centres. Results Forty-five clinicians (response rate of 51%) completed the questionnaire, and 19 clinicians were interviewed. The results showed that even though clinicians had a positive attitude towards prescribing E=M, only a few reported to regularly prescribe E=M to their patients. The 52 identified facilitators and barriers for implementation of E=M were categorised into four main themes: (1) beliefs toward the implementation of E=M (eg, clinicians knowledge and skills, and social support), (2) factors related to the patient perspective (eg, patient priorities or motivation), (3) factors related to the referral options (eg, knowledge of and trust in local referral options) and (4) practical considerations when implementing E=M (eg, time constraints). Conclusions Our study showed that even though many clinicians have a positive attitude toward an active lifestyle, many are not prescribing E=M on a regular basis. In order for clinicians to effectively implement E=M, strategies should focus on increasing clinicians E=M referral skills, improving clinicians knowledge of E=M referral options and develop a support system to ensure that E=M is high on the priority list of clinicians
Implementing Individually Tailored Prescription of Physical Activity in Routine Clinical Care:Protocol of the Physicians Implement Exercise = Medicine (PIE=M) Development and Implementation Project
BACKGROUND: The prescription of physical activity (PA) in clinical care has been advocated worldwide. This "exercise is medicine" (E=M) concept can be used to prevent, manage, and cure various lifestyle-related chronic diseases. Due to several challenges, E=M is not yet routinely implemented in clinical care. OBJECTIVE: This paper describes the rationale and design of the Physicians Implement Exercise = Medicine (PIE=M) study, which aims to facilitate the implementation of E=M in hospital care. METHODS: PIE=M consists of 3 interrelated work packages. First, levels and determinants of PA in different patient and healthy populations will be investigated using existing cohort data. The current implementation status, facilitators, and barriers of E=M will also be investigated using a mixed-methods approach among clinicians of participating departments from 2 diverse university medical centers (both located in a city, but one serving an urban population and one serving a more rural population). Implementation strategies will be connected to these barriers and facilitators using a systematic implementation mapping approach. Second, a generic E=M tool will be developed that will provide tailored PA prescription and referral. Requirements for this tool will be investigated among clinicians and department managers. The tool will be developed using an iterative design process in which all stakeholders reflect on the design of the E=M tool. Third, we will pilot-implement the set of implementation strategies, including the E=M tool, to test its feasibility in routine care of clinicians in these 2 university medical centers. An extensive learning process evaluation will be performed among clinicians, department managers, lifestyle coaches, and patients using a mixed-methods design based on the RE-AIM framework. RESULTS: This project was approved and funded by the Dutch grant provider ZonMW in April 2018. The project started in September 2018 and continues until December 2020 (depending on the course of the COVID-19 crisis). All data from the first work package have been collected and analyzed and are expected to be published in 2021. Results of the second work package are described. The manuscript is expected to be published in 2021. The third work package is currently being conducted in clinical practice in 4 departments of 2 university medical hospitals among clinicians, lifestyle coaches, hospital managers, and patients. Results are expected to be published in 2021. CONCLUSIONS: The PIE=M project addresses the potential of providing patients with PA advice to prevent and manage chronic disease, improve recovery, and enable healthy ageing by developing E=M implementation strategies, including an E=M tool, in routine clinical care. The PIE=M project will result in a blueprint of implementation strategies, including an E=M screening and referral tool, which aims to improve E=M referral by clinicians to improve patients' health, while minimizing the burden on clinicians
Clostridium difficile Infections amongst Patients with Haematological Malignancies: A Data Linkage Study
OBJECTIVES: Identify risk factors for Clostridium difficile infection (CDI) and assess CDI outcomes among Australian patients with a haematological malignancy. METHODS: A retrospective cohort study involving all patients admitted to hospitals in Western Australia with a haematological malignancy from July 2011 to June 2012. Hospital admission data were linked with all hospital investigated CDI case data. Potential risk factors were assessed by logistic regression. The risk of death within 60 and 90 days of CDI was assessed by Cox Proportional Hazards regression. RESULTS: There were 2085 patients of whom 65 had at least one CDI. Twenty percent of CDI cases were either community-acquired, indeterminate source or had only single-day admissions in the 28 days prior to CDI. Using logistic regression, having acute lymphocytic leukaemia, neutropenia and having had bacterial pneumonia or another bacterial infection were associated with CDI. CDI was associated with an increased risk of death within 60 and 90 days post CDI, but only two deaths had CDI recorded as an antecedent factor. Ribotyping information was available for 33 of the 65 CDIs. There were 19 different ribotypes identified. CONCLUSIONS: Neutropenia was strongly associated with CDI. While having CDI is a risk factor for death, in many cases it may not be a direct contributor to death but may reflect patients having higher morbidity. A wide variety of C. difficile ribotypes were found and community-acquired infection may be under-estimated in these patients
Improved detection of colibactin-induced mutations by genotoxic E. coli in organoids and colorectal cancer
Co-culture of intestinal organoids with a colibactin-producing pks+ E. coli strain (EcC) revealed mutational signatures also found in colorectal cancer (CRC). E. coli Nissle 1917 (EcN) remains a commonly used probiotic, despite harboring the pks operon and inducing double strand DNA breaks. We determine the mutagenicity of EcN and three CRC-derived pks+ E. coli strains with an analytical framework based on sequence characteristic of colibactin-induced mutations. All strains, including EcN, display varying levels of mutagenic activity. Furthermore, a machine learning approach attributing individual mutations to colibactin reveals that patients with colibactin-induced mutations are diagnosed at a younger age and that colibactin can induce a specific APC mutation. These approaches allow the sensitive detection of colibactin-induced mutations in βΌ12% of CRC genomes and even in whole exome sequencing data, representing a crucial step toward pinpointing the mutagenic activity of distinct pks+ E. coli strains
Autoimmune gastrointestinal complications in patients with Systemic Lupus Erythematosus: case series and literature review
The association of systemic lupus erythematosus (SLE) with gastrointestinal autoimmune diseases is rare, but has been described in the literature, mostly as case reports. However, some of these diseases may be very severe, thus a correct and early diagnosis with appropriate management are fundamental. We have analysed our data from the SLE patient cohort at University College Hospital London, established in 1978, identifying those patients with an associated autoimmune gastrointestinal disease. We have also undertaken a review of the literature describing the major autoimmune gastrointestinal pathologies which may be coincident with SLE, focusing on the incidence, clinical and laboratory (particularly antibody) findings, common aetiopathogenesis and complications
- β¦